Article

Neoadjuvant chemo affects PSA levels post-RP, but histology is unchanged

Weekly neoadjuvant chemotherapy with docetaxel (Taxotere) achieved aPSA response in almost 80% of a small group of high-risk prostate cancerpatients enrolled in a feasibility study of single-agent therapy.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
Woman typing on laptop | Image Credit: © Gorodenkoff - stock.adobe.com
Related Content
Enrollment goal met in phase 3 SOLAR-RECUR trial
November 22nd 2024

Enrollment goal met in phase 3 SOLAR-RECUR trial

Hannah Clarke
The trial is evaluating the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer following treatment with curative intent.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
FDA accepts sNDA for darolutamide plus ADT in mHSPC
November 21st 2024

FDA accepts sNDA for darolutamide plus ADT in mHSPC

Hannah Clarke
The sNDA is supported by data from the pivotal phase 3 ARANOTE trial.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
Dean Laganosky, M.D., named Urology Trailblazer for 2024
November 19th 2024

Dean Laganosky, M.D., named Urology Trailblazer for 2024

MidLantic Urology
This prestigious recognition is given to one urologist or administrator each year who has significantly contributed to the field of urology within the first ten years of their practice.
© 2024 MJH Life Sciences

All rights reserved.